The National Institute of Health and Clinical Excellence (NICE) has published new guidance for the month of October 2011. This month there is one technology appraisal that impacts upon primary care.
The ticagrelor for the treatment of acute coronary syndromes (ACS) technology appraisal (PDF) recommends ticagrelor (Brilique®) in combination with low-dose aspirin for up to a year as a possible treatment for some people with acute coronary syndromes.
The guidance defines the characteristics of the patients with ACS who are recommended for treatment noting that although this treatment costs more than other treatments, this was justified by the benefits it provided.
Action: Clinicians should be aware of this guideline. Primary care is likely to be requested to prescribe courses of this treatment to appropriate individuals.
|« "Specials" reimbursement changing||CV risk of ADHD drugs »|